Black Diamond Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Black Diamond Therapeutics' es Mark Velleca , nombrado en Sep 2023, tiene una permanencia de menos de un año. compensación anual total es $3.39M, compuesta por 5.3% salario y 94.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.083% de las acciones de la empresa, por valor de $254.47K. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 4 años, respectivamente.

Información clave

Mark Velleca

Chief Executive Officer (CEO)

US$3.4m

Compensación total

Porcentaje del salario del CEO	5.3%
Permanencia del CEO	less than a year
Participación del CEO	0.08%
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11

Black Diamond Therapeutics EPS misses by $0.16

May 07

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Jan 05

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Dec 01

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mark Velleca en comparación con los beneficios de Black Diamond Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$3m	US$180k	-US$82m
Sep 30 2023	n/a	n/a	-US$84m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	-US$87m
Dec 31 2022	US$65k	n/a	-US$91m
Sep 30 2022	n/a	n/a	-US$96m
Jun 30 2022	n/a	n/a	-US$109m
Mar 31 2022	n/a	n/a	-US$121m
Dec 31 2021	US$204k	n/a	-US$126m

Compensación vs. Mercado: La compensación total de Mark($USD3.39M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.45M).

Compensación vs. Ingresos: La compensación de Mark ha aumentado mientras la empresa no es rentable.

CEO

Mark Velleca (60 yo)

less than a year

Permanencia

US$3,387,383

Compensación

Dr. Mark A. Velleca, M. D., Ph. D., serves as President & Chief Executive Officer at Black Diamond Therapeutics, Inc. since September 16, 2023 and serves as its Chairman since December 2022. He has been an...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Velleca	CEO, President & Chairman	less than a year	US$3.39m	0.083% $ 216.8k
David M. Epstein	Co-Founder & Director	no data	US$2.02m	1.62% $ 4.3m
Fang Ni	CFO, Principal Financial Officer and Chief Business Officer	2.7yrs	US$1.49m	0.23% $ 598.0k
Sergey Yurasov	Chief Medical Officer	2.1yrs	US$1.23m	0% $ 0
Elizabeth Buck	Co-Founder & Chief Scientific Officer	2.9yrs	US$347.30k	sin datos
Brent Hatzis-Schoch	COO & General Counsel	5.2yrs	US$911.23k	0.015% $ 39.1k
Elizabeth Montgomery	Chief People Officer	2.4yrs	sin datos	sin datos
Melanie Morrison	Chief Development Officer	1.7yrs	sin datos	sin datos
Erika Jones	Senior VP of Finance & Corporate Controller	3.5yrs	sin datos	0.0054% $ 14.2k

2.5yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BDTX se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Velleca	CEO, President & Chairman	2.9yrs	US$3.39m	0.083% $ 216.8k
David M. Epstein	Co-Founder & Director	7.8yrs	US$2.02m	1.62% $ 4.3m
Ali Behbahani	Independent Director	5.6yrs	US$68.14k	0.097% $ 254.3k
Garry Menzel	Independent Director	7.3yrs	US$75.35k	0.14% $ 357.2k
Kapil Dhingra	Independent Director	3.5yrs	US$109.35k	0.018% $ 46.6k
Samarth Kulkarni	Lead Independent Director	4.7yrs	US$59.35k	0% $ 0
Prakash Raman	Independent Director	less than a year	sin datos	0.0041% $ 10.7k
Shannon Campbell	Independent Director	less than a year	sin datos	0.0036% $ 9.4k

4.1yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de BDTX se considera experimentada (4 años de antigüedad promedio).

Black Diamond Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Co-Founder & Director notifies of intention to sell stock

Black Diamond Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board

Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes

Key Executive recently bought US$72k worth of stock

Black Diamond Therapeutics, Inc. Announces Changes to Board of Directors

Recent updates

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Co-Founder & Director notifies of intention to sell stock

New major risk - Shareholder dilution

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

Black Diamond Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Price target increased by 9.4% to US$11.60

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

New minor risk - Share price stability

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

New minor risk - Market cap size

Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes

Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

New major risk - Financial position

New minor risk - Shareholder dilution

New major risk - Share price stability

Black Diamond Therapeutics, Inc. Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Price target increased by 38% to US$9.33

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Key Executive recently bought US$72k worth of stock

Black Diamond Therapeutics, Inc. Announces Changes to Board of Directors

High number of new directors

Black Diamond Therapeutics, Inc. Appoints as Melanie Morrison as Senior Vice President, Development Operations

Black Diamond Therapeutics, Inc. Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Price target decreased to US$7.00

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Key Executive recently bought US$61k worth of stock

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Index

Black Diamond Therapeutics Appoints Sergey Yurasov as Chief Medical Officer

High number of new directors

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

Price target decreased to US$8.00

High number of new directors

Black Diamond Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of BDTX-1535

Black Diamond Therapeutics, Inc. Announces Board Changes

Price target decreased to US$21.60

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

Executive Officer Thomas Leggett has left the company

Price target decreased to US$42.83

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Growth Index

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Black Diamond Therapeutics, Inc. Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

COO & General Counsel exercised options and sold US$99k worth of stock

Black Diamond Therapeutics EPS misses by $0.16

COO & General Counsel exercised options and sold US$89k worth of stock

COO & General Counsel exercised options and sold US$94k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

COO & General Counsel exercised options and sold US$98k worth of stock

Diamond Therapeutics Signs Agreement with McGill University for Research on Low-Dose LSD

Black Diamond Therapeutics, Inc. Appoints Kapil Dhingra to Board of Directors

New 90-day low: US$28.62

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Co-Founder notifies of intention to sell stock

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Black Diamond Therapeutics, Inc. Provides Update on Gbm Program and Presents Pre-Clinical Data At the 2020 Sno Annual Meeting

Black Diamond nominates development candidate for glioblastoma program

Chief Financial Officer exercised options and sold US$66k worth of stock

Black Diamond Therapeutics Provides Corporate Update

New 90-day high: US$34.01

Black Diamond Therapeutics EPS beats by $0.02